ArticleScientific reports2026
Hypoxia-induced upregulation of lncRNA SLC9A3-AS1 promotes lung adenocarcinoma progression through the miR-506-5p/ASPH/NOTCH1 pathway.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Lung adenocarcinoma (LUAD) is a major cause of cancer-related mortality worldwide. Understanding the mechanism of LUAD progression will aid in the development of therapeutic approaches targeting this malignancy. Hypoxia is characteristic of solid tumors and contributes significantly to LUAD progression, although the molecular mechanisms involved have not been fully elucidated. Long noncoding RNAs (lncRNAs) are key regulators of cancer progression. Here, we identify SLC9A3-AS1 as a previously unrecognized hypoxia-induced lncRNA that is aberrantly upregulated in LUAD tissues. Functional analyses demonstrated that SLC9A3-AS1 promotes LUAD cell proliferation, migration, and invasion in vitro, as well as tumor growth in vivo. Mechanistically, SLC9A3-AS1 acts as a competing endogenous RNA (ceRNA) by binding to miR-506-5p, alleviating the post-transcriptional repression of aspartate β-hydroxylase (ASPH) and activating NOTCH1 signaling. ASPH overexpression or miR-506-5p inhibition counteracts the effects of SLC9A3-AS1 knockdown, restoring LUAD cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) capacity. Furthermore, we report that SLC9A3-AS1 is a hypoxia-responsive gene that is transcriptionally activated by hypoxia-inducible factor-1α (HIF-1α) in LUAD cells. Collectively, these results identify SLC9A3-AS1 as a key hypoxia-induced regulator of LUAD progression and reveal a miR-506-5p/ASPH/NOTCH1 signaling pathway that drives oncogenic activity. These findings provide new insights for the diagnosis and treatment of LUAD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.